Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,942 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K, Makino T, Takahashi T, Kawashima A, Haruna M, Hirata M, Ueyama A, Iwahori K, Satoh T, Kurokawa Y, Eguchi H, Doki Y, Wada H. Nose Y, et al. Among authors: wada h. Cancer Immunol Immunother. 2023 Jan;72(1):169-181. doi: 10.1007/s00262-022-03240-2. Epub 2022 Jul 1. Cancer Immunol Immunother. 2023. PMID: 35776160 Free PMC article.
NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, Doki Y, Yasui M, Sugita Y, Yasuda T, Yano M, Ono T, Chen YT, Higashiyama M, Gnjatic S, Old LJ, Nakayama E, Monden M. Fujita S, et al. Among authors: wada h. Clin Cancer Res. 2004 Oct 1;10(19):6551-8. doi: 10.1158/1078-0432.CCR-04-0819. Clin Cancer Res. 2004. PMID: 15475443
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M. Yamamoto T, et al. Among authors: wada h. Clin Cancer Res. 2004 Dec 1;10(23):7884-95. doi: 10.1158/1078-0432.CCR-04-0794. Clin Cancer Res. 2004. PMID: 15585621
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, Kumon H, Tsuji K, Iwatsuki K, Shiku H, Ritter G, Murphy R, Hoffman E, Old LJ, Monden M, Nakayama E. Kawabata R, et al. Among authors: wada h. Int J Cancer. 2007 May 15;120(10):2178-84. doi: 10.1002/ijc.22583. Int J Cancer. 2007. PMID: 17278093 Free article. Clinical Trial.
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E. Uenaka A, et al. Among authors: wada h. Cancer Immun. 2007 Apr 19;7:9. Cancer Immun. 2007. PMID: 17441676 Free PMC article. Clinical Trial.
Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E. Wada H, et al. Int J Cancer. 2008 Nov 15;123(10):2362-9. doi: 10.1002/ijc.23810. Int J Cancer. 2008. PMID: 18729190 Free article. Clinical Trial.
[Cancer vaccine].
Wada H, Doki Y, Nakayama E. Wada H, et al. Nihon Rinsho. 2008 Oct;66(10):2004-7. Nihon Rinsho. 2008. PMID: 18939504 Review. Japanese.
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, Uenaka A, Nakamura Y, Fujiwara S, Mizuno N, Saika T, Ritter E, Yamasaki M, Miyata H, Ritter G, Murphy R, Venhaus R, Pan L, Old LJ, Doki Y, Nakayama E. Kawada J, et al. Among authors: wada h. Int J Cancer. 2012 Feb 1;130(3):584-92. doi: 10.1002/ijc.26074. Epub 2011 May 25. Int J Cancer. 2012. PMID: 21413013 Free article.
Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer.
Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y, Sakakibara M, Kanto T, Shimosegawa E, Hatazawa J, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. Fujiwara S, et al. Among authors: wada h. J Immunother. 2012 Jul;35(6):513-21. doi: 10.1097/CJI.0b013e3182619cb4. J Immunother. 2012. PMID: 22735809 Clinical Trial.
[Immune monitoring and cancer vaccine].
Wada H, Doki Y, Nakayama E. Wada H, et al. Nihon Rinsho. 2012 Dec;70(12):2183-8. Nihon Rinsho. 2012. PMID: 23259394 Review. Japanese.
3,942 results